Page 3 - Agvhd News Today

Dr. Gooptu explains the risk factors associated with both acute and chronic GVHD.

Eno-Abasi Inyang, PharmD, BCPS, BCOP provides an overview of the various conditioning regimens employed for allogeneic stem cell transplantation.

Clinical pearls for community oncologists regarding treatment selection and sequencing in chronic GvHD patients.

Addressing patient monitoring in chronic GvHD, including therapy adjustment indicators and frequency.

The FDA has released a complete response letter to its biologics license application resubmission, indicating that it needs more data to support approval for remestemcel-L for the treatment of pediatric patients with steroid-refractory acute graft-vs-host disease.

Bonnie Dirr, APRN, introduces a clinical scenario of a patient who received an allogeneic stem cell transplant from a sibling donor to begin the panel’s discussion of graft versus host disease.

Mahasweta Gooptu, MD, reviews statistics on graft versus host disease and explains the desired graft versus leukemia effect.

Exploring FDA-approved treatment options for patients with chronic GvHD, with a focus on trial data and adverse effects.

Insights on treatment strategies and goals for initial chronic GvHD management, including treatment selection rationale and dosing.

Experienced clinicians discuss the future of acute GvHD treatment, focusing on gaps in patient care and potential therapy options.